Gabapentin to Treat Itch in Patients With Liver Disease

Cirrhosis Clinical Trial

Official title:

Study of Gabapentin for the Pruritus of Cholestasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00058890
• Other study ID #: R03 --9618 (completed 2005)
• Secondary ID: R03DK055618
• Status: Completed
• Phase: Phase 3
• First received: April 14, 2003
• Last updated: October 12, 2017
• Start date: November 2000
• Est. completion date: January 2004

Study information

• Verified date: October 2017
• Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the effect of the medication gabapentin to treat itching secondary to liver disease is being studied.

There are some funds to cover travel expenses for patients who are not from New York (NY).

Gabapentin is approved to treat seizures in human beings. In this study, patients with liver disease who meet inclusion criteria are admitted to the research hospital of the New York Presbyterian Hospital to record scratching behavior by the use of a machine designed for that purpose. Blood work will be obtained. After completion of recording, patients are assigned by chance to receive active medication or placebo (a capsule that does not contain active medication). The patients will come to the outpatient office of the research hospital 2 weeks into the study for an interview and blood work. After 4 weeks, patients are readmitted to the hospital to record scratching behavior. After data are collected, the code is broken, if patient had been on inactive drug, active drug will be supplied as per protocol for 4 weeks. Blood work will be obtained. If patient had been randomized to active medication, the study will provide one week supply of drug. After that, the referring physician, with whom the study was previously discussed, could prescribe the medication as it is available.

Description:

Double-blind, randomized, placebo-controlled study of gabapentin for the pruritus of cholestasis. Duration: 4 weeks. Some travel funds available for patients from out of the NY area for all the visits. Hospitalization at baseline and after 4 weeks of treatment. One outpatient department visit at week 2.

All patients have to be referred by their physician, who will receive a summary of the results at the end of the patient's study participation.

If patients are randomized to active drug and respond to it with decrease in pruritus, a one week supply of medication is given. The referring physician could prescribe the drug for long term use. If the patient is randomized to placebo they can be treated with active medication provided by the study for 4 weeks, at end of which, the drug could be prescribed by referring physician if the patient responds to the drug with decrease in the pruritus.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 2004
• Est. primary completion date: January 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria include:

• Patients from ages 18 to 80 with chronic pruritus secondary to liver disease

Patients must have:

• a normal chest X- ray during the previous year

• normal thyroid function tests (treated thyroid dysfunction is acceptable)

• controlled diabetes, if diabetes mellitus is present

• negative fecal occult blood within the previous year

Exclusion criteria include:

• history of hepatic encephalopathy

• decompensated liver disease as suggested by ascites and history of variceal bleeding

• malignancy

• inability to practice contraception

• pregnancy

• creatinine > 1.7 mg/dl

• hemoglobin < 10mg/dl

• S/P liver transplantation

• HIV infection

Related Conditions & MeSH terms

• Cholestasis
• Cirrhosis
• Fibrosis
• Itching
• Liver Disease
• Liver Diseases
• Pruritus

Intervention

Drug:
• Gabapentin
Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
• Placebo

Locations

Country	Name	City	State
United States	Columbia University College of Physicians and Surgeons	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006 Nov;44(5):1317-23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in scratching activity monitoring system	A scratching activity monitoring system specifically designed to record scratching behavior independent of gross body movement	4 weeks
Secondary	Change in visual analogue scale for pruritus		4 weeks